AI entity
Crinetics Pharmaceuticals is most often covered alongside Advanced Micro Devices, which appears in 1 of these 2 stories. Each story carries 9.5 original sources on average, compared with 3 for the broader beat in this window. That works out to roughly 0.1 stories per week across a 135-day span.
Last mentioned: Jul 31, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Crinetics Pharmaceuticals is most often covered alongside Advanced Micro Devices, which appears in 1 of these 2 stories. Each story carries 9.5 original sources on average, compared with 3 for the broader beat in this window. That works out to roughly 0.1 stories per week across a 135-day span. Their average consequence score of 7 runs above the beat's 6.7 for that window. The clearest coverage concentration is ai-models: 1 of 2 stories, with the rest divided among 1 other category. This profile follows 2 AI stories mentioning Crinetics Pharmaceuticals across the period from February 27, 2026 to July 11, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 1254 AI stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Crinetics Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
EU Expansion
Positive CHMP opinion received, enabling commercialization in the European Union.
Public Offering
Crinetics raises capital, bringing total cash position to $1.4 billion.
Q4 Milestone
Over 200 enrollment forms and 125 unique prescribers recorded for Palsonify.
Palsonify Launch
Crinetics initiates U.S. commercial launch of Palsonify for acromegaly.
Even a jaw-dropping 1,800% YoY operating profit forecast from Samsung couldn’t prop up AI stocks on July 7, as the sector’s inflated valuations met a harsh reality check. The 6.9% drop in Seoul and subsequent 6-10% declines in U.S. chipmakers signal that the AI industry must now prove its ROI potential to justify its sky-high market caps.
Source: whdh.com · nvdaily.com
Q4 2025 earnings reports highlight a strategic shift toward AI-integrated hardware and high-margin services, with Aeva securing a pivotal NVIDIA partnership and Arlo achieving record SaaS metrics. Meanwhile, Crinetics successfully launched Palsonify, backed by a massive $1.4 billion cash reserve to fuel global expansion.
Crinetics Pharmaceuticals is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
